| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Noppawan Tunsirimas, Pornjira Pariwatcharakul, Somrak Choovanichvong, Woraphat Ratta-Aph. Clozapine-induced agranulocytosis and leukopenia: Incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand. Asian journal of psychiatry. vol 41. 2019-08-13. PMID:30856469. |
the present study aimed to investigate the incidence of agranulocytosis and leukopenia and its associated factors in thai schizophrenia patients treated with clozapine and the rate of hematologic adverse events monitored in clinical practice. |
2019-08-13 |
2023-08-13 |
Not clear |
| René S Kahn, Inge Winter van Rossum, Stefan Leucht, Philip McGuire, Shon W Lewis, Marion Leboyer, Celso Arango, Paola Dazzan, Richard Drake, Stephan Heres, Covadonga M Díaz-Caneja, Dan Rujescu, Mark Weiser, Silvana Galderisi, Birte Glenthøj, Marinus J C Eijkemans, W Wolfgang Fleischhacker, Shitij Kapur, Iris E Somme. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. The lancet. Psychiatry. vol 5. issue 10. 2019-08-09. PMID:30115598. |
amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (optimise): a three-phase switching study. |
2019-08-09 |
2023-08-13 |
Not clear |
| René S Kahn, Inge Winter van Rossum, Stefan Leucht, Philip McGuire, Shon W Lewis, Marion Leboyer, Celso Arango, Paola Dazzan, Richard Drake, Stephan Heres, Covadonga M Díaz-Caneja, Dan Rujescu, Mark Weiser, Silvana Galderisi, Birte Glenthøj, Marinus J C Eijkemans, W Wolfgang Fleischhacker, Shitij Kapur, Iris E Somme. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. The lancet. Psychiatry. vol 5. issue 10. 2019-08-09. PMID:30115598. |
whether switching antipsychotics or early use of clozapine improves outcome in (first-episode) schizophrenia is unknown. |
2019-08-09 |
2023-08-13 |
Not clear |
| Suraj Pathak, Scott Cherry, Samreen Samad, Ambreen Afta. Successful clozapine rechallenge in a patient with suspected drug induced lupus. BMJ case reports. vol 12. issue 4. 2019-08-05. PMID:30948402. |
clozapine is the most effective treatment for patients with refractory schizophrenia. |
2019-08-05 |
2023-08-13 |
Not clear |
| François R Girardin, Antoine Poncet, Arnaud Perrier, Nathalie Vernaz, Mark Pletscher, Caroline F Samer, Jeffrey A Lieberman, Jean Villar. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. The pharmacogenomics journal. vol 19. issue 2. 2019-08-02. PMID:29298994. |
less than 1% of adult patients with schizophrenia taking clozapine develop agranulocytosis, and most of these cases occur within the first weeks of treatment. |
2019-08-02 |
2023-08-13 |
human |
| François R Girardin, Antoine Poncet, Arnaud Perrier, Nathalie Vernaz, Mark Pletscher, Caroline F Samer, Jeffrey A Lieberman, Jean Villar. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. The pharmacogenomics journal. vol 19. issue 2. 2019-08-02. PMID:29298994. |
the current study aimed to evaluate the cost-effectiveness, from a healthcare provider's perspective, of an hla genotype-guided approach in patients with treatment-resistant schizophrenia who were taking clozapine and to compare the results with the current absolute neutrophil count monitoring (ancm) schemes used in the usa. |
2019-08-02 |
2023-08-13 |
human |
| Carolyn Beth McNabb, Rob Kydd, Frederick Sundram, Ian Soosay, Bruce Roy Russel. Differences in white matter connectivity between treatment-resistant and treatment-responsive subtypes of schizophrenia. Psychiatry research. Neuroimaging. vol 282. 2019-07-25. PMID:30412902. |
these data reveal differences in diffusion measures between flr and those eligible for clozapine and suggest that lower fa and greater rd in the corpus callosum could exist as a biomarker of treatment resistance in people with schizophrenia. |
2019-07-25 |
2023-08-13 |
human |
| Ismael Olmos, Manuel Ibarra, Marta Vázquez, Cecilia Maldonado, Pietro Fagiolino, Gustavo Giachett. Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. BioMed research international. vol 2019. 2019-07-22. PMID:30956977. |
population pharmacokinetics of clozapine and norclozapine and switchability assessment between brands in uruguayan patients with schizophrenia. |
2019-07-22 |
2023-08-13 |
Not clear |
| Ismael Olmos, Manuel Ibarra, Marta Vázquez, Cecilia Maldonado, Pietro Fagiolino, Gustavo Giachett. Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. BioMed research international. vol 2019. 2019-07-22. PMID:30956977. |
clozapine (czp) is an atypical antipsychotic agent commonly used in the treatment of schizophrenia. |
2019-07-22 |
2023-08-13 |
Not clear |
| Wei Wang, Mengru Bai, Ting Jiang, Cui Li, Ping Li, Hui Zhou, Zemin Wang, Liping Li, Huidi Jian. Clozapine-induced reduction of l-carnitine reabsorption via inhibition/down-regulation of renal carnitine/organic cation transporter 2 contributes to liver lipid metabolic disorder in mice. Toxicology and applied pharmacology. vol 363. 2019-07-18. PMID:30465787. |
clozapine, an atypical antipsychotic drug, is widely utilized for the treatment of schizophrenia; however, clozapine-induced metabolic disorders, such as fatty liver and weight gain, warrant increased attention. |
2019-07-18 |
2023-08-13 |
mouse |
| Jibran Y Khokhar, Angela M Henricks, Emily D K Sullivan, Alan I Gree. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in pharmacology (San Diego, Calif.). vol 82. 2019-07-17. PMID:29413518. |
clozapine, the first atypical antipsychotic, is a highly effective medication for patients with schizophrenia who do not respond to other antipsychotics. |
2019-07-17 |
2023-08-13 |
Not clear |
| Jibran Y Khokhar, Angela M Henricks, Emily D K Sullivan, Alan I Gree. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in pharmacology (San Diego, Calif.). vol 82. 2019-07-17. PMID:29413518. |
in addition to its effects in treatment-resistant schizophrenia, clozapine has been shown to decrease suicidality, which occurs at an increased rate in patients with schizophrenia. |
2019-07-17 |
2023-08-13 |
Not clear |
| Jibran Y Khokhar, Angela M Henricks, Emily D K Sullivan, Alan I Gree. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in pharmacology (San Diego, Calif.). vol 82. 2019-07-17. PMID:29413518. |
still preliminary, but consistent data, also suggest that clozapine limits substance use in these patients, an important effect since substance use disorders are common in patients with schizophrenia and are associated with a poor outcome, including an increased risk for suicide and poor response to treatment. |
2019-07-17 |
2023-08-13 |
Not clear |
| David Dickens, Steffen Rädisch, George N Chiduza, Athina Giannoudis, Michael J Cross, Hassan Malik, Elke Schaeffeler, Rowena L Sison-Young, Emma L Wilkinson, Christopher E Goldring, Matthias Schwab, Munir Pirmohamed, Anne T Nie. Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process. Molecular pharmaceutics. vol 15. issue 8. 2019-07-16. PMID:29944835. |
the weak base antipsychotic clozapine is the most effective medication for treating refractory schizophrenia. |
2019-07-16 |
2023-08-13 |
human |
| Paul J Harriso. D-Amino Acid Oxidase Inhibition: A New Glutamate Twist for Clozapine Augmentation in Schizophrenia? Biological psychiatry. vol 84. issue 6. 2019-06-19. PMID:30165950. |
d-amino acid oxidase inhibition: a new glutamate twist for clozapine augmentation in schizophrenia? |
2019-06-19 |
2023-08-13 |
Not clear |
| Jianmeng Song, Carol Borlido, Vincenzo De Luca, Leah Burton, Gary Remingto. Patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. Psychiatry research. vol 274. 2019-06-13. PMID:30852435. |
patient versus rater evaluation of symptom severity in treatment resistant schizophrenia receiving clozapine. |
2019-06-13 |
2023-08-13 |
Not clear |
| A Zarina Kraal, Kristen M Ward, Vicki L Ellingro. Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders. Psychopharmacology bulletin. vol 47. issue 2. 2019-05-30. PMID:28626268. |
these results suggest that female schizophrenia patients taking clozapine or olanzapine represent a group at uniquely high risk for metabolic dysfunction and future adverse cardiovascular outcomes, and warrant close monitoring by clinicians to prevent worsening of metabolic risk through proper monitoring and interventions. |
2019-05-30 |
2023-08-13 |
human |
| Ruth Rayikanti, Iga Lentowicz, Badari Birur, Li L. Combined Antipsychotics and Electroconvulsive Therapy in an Acutely Psychotic Patient with Treatment-resistant Schizophrenia. Psychopharmacology bulletin. vol 47. issue 2. 2019-05-30. PMID:28626273. |
treatment of patients with treatment-resistant schizophrenia (trs), who fail to respond to multiple antipsychotic trials, including clozapine (clz), is challenging. |
2019-05-30 |
2023-08-13 |
Not clear |
| Zoltán Rihmer, Attila Németh, Tamás Kurimay, Dóra Perczel-Forintos, György Purebl, Péter Döm. [Recognition, care and prevention of suicidal behaviour in adults]. Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata. vol 32. issue 1. 2019-05-23. PMID:28424378. |
treatment with clozapine is effective in reducing suicidal behaviour in patients with schizophrenia. |
2019-05-23 |
2023-08-13 |
Not clear |
| Hélène Verdoux, Clélia Quiles, Christian J Bachmann, Dan Siskin. Prescriber and institutional barriers and facilitators of clozapine use: A systematic review. Schizophrenia research. vol 201. 2019-05-20. PMID:29880453. |
as clozapine is under-prescribed in persons with treatment-resistant schizophrenia (trs), it is necessary to better identify the determinants of health inequalities in access to clozapine use. |
2019-05-20 |
2023-08-13 |
Not clear |